Medical Care
Global Spinal Muscular Atrophy (SMA) Drugs Market Research Report 2025
- Jun 28, 25
- ID: 346342
- Pages: 64
- Figures: 60
- Views: 2
The global market for Spinal Muscular Atrophy (SMA) Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Spinal Muscular Atrophy (SMA), also known as spinal muscular atrophy, is a type of disease in which the degeneration of motor neurons in the anterior horn of the spinal cord leads to muscle weakness and muscular atrophy.The Spinal muscular atrophy drugs Can effectively alleviate the symptoms of the disease.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Spinal Muscular Atrophy (SMA) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Spinal Muscular Atrophy (SMA) Drugs.
The Spinal Muscular Atrophy (SMA) Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Spinal Muscular Atrophy (SMA) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Spinal Muscular Atrophy (SMA) Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Biogen
Novartis
Genentech
Segment by Type
Oral Medicine
Injection Medicine
Segment by Application
Baby
Child
Adult
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Spinal Muscular Atrophy (SMA) Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Spinal Muscular Atrophy (SMA), also known as spinal muscular atrophy, is a type of disease in which the degeneration of motor neurons in the anterior horn of the spinal cord leads to muscle weakness and muscular atrophy.The Spinal muscular atrophy drugs Can effectively alleviate the symptoms of the disease.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Spinal Muscular Atrophy (SMA) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Spinal Muscular Atrophy (SMA) Drugs.
The Spinal Muscular Atrophy (SMA) Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Spinal Muscular Atrophy (SMA) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Spinal Muscular Atrophy (SMA) Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Biogen
Novartis
Genentech
Segment by Type
Oral Medicine
Injection Medicine
Segment by Application
Baby
Child
Adult
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Spinal Muscular Atrophy (SMA) Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Spinal Muscular Atrophy (SMA) Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Oral Medicine
1.2.3 Injection Medicine
1.3 Market by Application
1.3.1 Global Spinal Muscular Atrophy (SMA) Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Baby
1.3.3 Child
1.3.4 Adult
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Spinal Muscular Atrophy (SMA) Drugs Market Perspective (2020-2031)
2.2 Global Spinal Muscular Atrophy (SMA) Drugs Growth Trends by Region
2.2.1 Global Spinal Muscular Atrophy (SMA) Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Spinal Muscular Atrophy (SMA) Drugs Historic Market Size by Region (2020-2025)
2.2.3 Spinal Muscular Atrophy (SMA) Drugs Forecasted Market Size by Region (2026-2031)
2.3 Spinal Muscular Atrophy (SMA) Drugs Market Dynamics
2.3.1 Spinal Muscular Atrophy (SMA) Drugs Industry Trends
2.3.2 Spinal Muscular Atrophy (SMA) Drugs Market Drivers
2.3.3 Spinal Muscular Atrophy (SMA) Drugs Market Challenges
2.3.4 Spinal Muscular Atrophy (SMA) Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Spinal Muscular Atrophy (SMA) Drugs Players by Revenue
3.1.1 Global Top Spinal Muscular Atrophy (SMA) Drugs Players by Revenue (2020-2025)
3.1.2 Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Spinal Muscular Atrophy (SMA) Drugs Revenue
3.4 Global Spinal Muscular Atrophy (SMA) Drugs Market Concentration Ratio
3.4.1 Global Spinal Muscular Atrophy (SMA) Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Spinal Muscular Atrophy (SMA) Drugs Revenue in 2024
3.5 Global Key Players of Spinal Muscular Atrophy (SMA) Drugs Head office and Area Served
3.6 Global Key Players of Spinal Muscular Atrophy (SMA) Drugs, Product and Application
3.7 Global Key Players of Spinal Muscular Atrophy (SMA) Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Spinal Muscular Atrophy (SMA) Drugs Breakdown Data by Type
4.1 Global Spinal Muscular Atrophy (SMA) Drugs Historic Market Size by Type (2020-2025)
4.2 Global Spinal Muscular Atrophy (SMA) Drugs Forecasted Market Size by Type (2026-2031)
5 Spinal Muscular Atrophy (SMA) Drugs Breakdown Data by Application
5.1 Global Spinal Muscular Atrophy (SMA) Drugs Historic Market Size by Application (2020-2025)
5.2 Global Spinal Muscular Atrophy (SMA) Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Spinal Muscular Atrophy (SMA) Drugs Market Size (2020-2031)
6.2 North America Spinal Muscular Atrophy (SMA) Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2020-2025)
6.4 North America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Spinal Muscular Atrophy (SMA) Drugs Market Size (2020-2031)
7.2 Europe Spinal Muscular Atrophy (SMA) Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2020-2025)
7.4 Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size (2020-2031)
8.2 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size (2020-2031)
9.2 Latin America Spinal Muscular Atrophy (SMA) Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2020-2025)
9.4 Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size (2020-2031)
10.2 Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Details
11.1.2 Biogen Business Overview
11.1.3 Biogen Spinal Muscular Atrophy (SMA) Drugs Introduction
11.1.4 Biogen Revenue in Spinal Muscular Atrophy (SMA) Drugs Business (2020-2025)
11.1.5 Biogen Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Spinal Muscular Atrophy (SMA) Drugs Introduction
11.2.4 Novartis Revenue in Spinal Muscular Atrophy (SMA) Drugs Business (2020-2025)
11.2.5 Novartis Recent Development
11.3 Genentech
11.3.1 Genentech Company Details
11.3.2 Genentech Business Overview
11.3.3 Genentech Spinal Muscular Atrophy (SMA) Drugs Introduction
11.3.4 Genentech Revenue in Spinal Muscular Atrophy (SMA) Drugs Business (2020-2025)
11.3.5 Genentech Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Spinal Muscular Atrophy (SMA) Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Oral Medicine
1.2.3 Injection Medicine
1.3 Market by Application
1.3.1 Global Spinal Muscular Atrophy (SMA) Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Baby
1.3.3 Child
1.3.4 Adult
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Spinal Muscular Atrophy (SMA) Drugs Market Perspective (2020-2031)
2.2 Global Spinal Muscular Atrophy (SMA) Drugs Growth Trends by Region
2.2.1 Global Spinal Muscular Atrophy (SMA) Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Spinal Muscular Atrophy (SMA) Drugs Historic Market Size by Region (2020-2025)
2.2.3 Spinal Muscular Atrophy (SMA) Drugs Forecasted Market Size by Region (2026-2031)
2.3 Spinal Muscular Atrophy (SMA) Drugs Market Dynamics
2.3.1 Spinal Muscular Atrophy (SMA) Drugs Industry Trends
2.3.2 Spinal Muscular Atrophy (SMA) Drugs Market Drivers
2.3.3 Spinal Muscular Atrophy (SMA) Drugs Market Challenges
2.3.4 Spinal Muscular Atrophy (SMA) Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Spinal Muscular Atrophy (SMA) Drugs Players by Revenue
3.1.1 Global Top Spinal Muscular Atrophy (SMA) Drugs Players by Revenue (2020-2025)
3.1.2 Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Spinal Muscular Atrophy (SMA) Drugs Revenue
3.4 Global Spinal Muscular Atrophy (SMA) Drugs Market Concentration Ratio
3.4.1 Global Spinal Muscular Atrophy (SMA) Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Spinal Muscular Atrophy (SMA) Drugs Revenue in 2024
3.5 Global Key Players of Spinal Muscular Atrophy (SMA) Drugs Head office and Area Served
3.6 Global Key Players of Spinal Muscular Atrophy (SMA) Drugs, Product and Application
3.7 Global Key Players of Spinal Muscular Atrophy (SMA) Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Spinal Muscular Atrophy (SMA) Drugs Breakdown Data by Type
4.1 Global Spinal Muscular Atrophy (SMA) Drugs Historic Market Size by Type (2020-2025)
4.2 Global Spinal Muscular Atrophy (SMA) Drugs Forecasted Market Size by Type (2026-2031)
5 Spinal Muscular Atrophy (SMA) Drugs Breakdown Data by Application
5.1 Global Spinal Muscular Atrophy (SMA) Drugs Historic Market Size by Application (2020-2025)
5.2 Global Spinal Muscular Atrophy (SMA) Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Spinal Muscular Atrophy (SMA) Drugs Market Size (2020-2031)
6.2 North America Spinal Muscular Atrophy (SMA) Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2020-2025)
6.4 North America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Spinal Muscular Atrophy (SMA) Drugs Market Size (2020-2031)
7.2 Europe Spinal Muscular Atrophy (SMA) Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2020-2025)
7.4 Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size (2020-2031)
8.2 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size (2020-2031)
9.2 Latin America Spinal Muscular Atrophy (SMA) Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2020-2025)
9.4 Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size (2020-2031)
10.2 Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Details
11.1.2 Biogen Business Overview
11.1.3 Biogen Spinal Muscular Atrophy (SMA) Drugs Introduction
11.1.4 Biogen Revenue in Spinal Muscular Atrophy (SMA) Drugs Business (2020-2025)
11.1.5 Biogen Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Spinal Muscular Atrophy (SMA) Drugs Introduction
11.2.4 Novartis Revenue in Spinal Muscular Atrophy (SMA) Drugs Business (2020-2025)
11.2.5 Novartis Recent Development
11.3 Genentech
11.3.1 Genentech Company Details
11.3.2 Genentech Business Overview
11.3.3 Genentech Spinal Muscular Atrophy (SMA) Drugs Introduction
11.3.4 Genentech Revenue in Spinal Muscular Atrophy (SMA) Drugs Business (2020-2025)
11.3.5 Genentech Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Spinal Muscular Atrophy (SMA) Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Oral Medicine
Table 3. Key Players of Injection Medicine
Table 4. Global Spinal Muscular Atrophy (SMA) Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Spinal Muscular Atrophy (SMA) Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Spinal Muscular Atrophy (SMA) Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Region (2020-2025)
Table 8. Global Spinal Muscular Atrophy (SMA) Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Region (2026-2031)
Table 10. Spinal Muscular Atrophy (SMA) Drugs Market Trends
Table 11. Spinal Muscular Atrophy (SMA) Drugs Market Drivers
Table 12. Spinal Muscular Atrophy (SMA) Drugs Market Challenges
Table 13. Spinal Muscular Atrophy (SMA) Drugs Market Restraints
Table 14. Global Spinal Muscular Atrophy (SMA) Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Players (2020-2025)
Table 16. Global Top Spinal Muscular Atrophy (SMA) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Spinal Muscular Atrophy (SMA) Drugs as of 2024)
Table 17. Ranking of Global Top Spinal Muscular Atrophy (SMA) Drugs Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Spinal Muscular Atrophy (SMA) Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Spinal Muscular Atrophy (SMA) Drugs, Headquarters and Area Served
Table 20. Global Key Players of Spinal Muscular Atrophy (SMA) Drugs, Product and Application
Table 21. Global Key Players of Spinal Muscular Atrophy (SMA) Drugs, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Type (2020-2025)
Table 25. Global Spinal Muscular Atrophy (SMA) Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Type (2026-2031)
Table 27. Global Spinal Muscular Atrophy (SMA) Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Application (2020-2025)
Table 29. Global Spinal Muscular Atrophy (SMA) Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Application (2026-2031)
Table 31. North America Spinal Muscular Atrophy (SMA) Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Spinal Muscular Atrophy (SMA) Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 46. Biogen Company Details
Table 47. Biogen Business Overview
Table 48. Biogen Spinal Muscular Atrophy (SMA) Drugs Product
Table 49. Biogen Revenue in Spinal Muscular Atrophy (SMA) Drugs Business (2020-2025) & (US$ Million)
Table 50. Biogen Recent Development
Table 51. Novartis Company Details
Table 52. Novartis Business Overview
Table 53. Novartis Spinal Muscular Atrophy (SMA) Drugs Product
Table 54. Novartis Revenue in Spinal Muscular Atrophy (SMA) Drugs Business (2020-2025) & (US$ Million)
Table 55. Novartis Recent Development
Table 56. Genentech Company Details
Table 57. Genentech Business Overview
Table 58. Genentech Spinal Muscular Atrophy (SMA) Drugs Product
Table 59. Genentech Revenue in Spinal Muscular Atrophy (SMA) Drugs Business (2020-2025) & (US$ Million)
Table 60. Genentech Recent Development
Table 61. Research Programs/Design for This Report
Table 62. Key Data Information from Secondary Sources
Table 63. Key Data Information from Primary Sources
Table 64. Authors List of This Report
List of Figures
Figure 1. Spinal Muscular Atrophy (SMA) Drugs Picture
Figure 2. Global Spinal Muscular Atrophy (SMA) Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Type: 2024 VS 2031
Figure 4. Oral Medicine Features
Figure 5. Injection Medicine Features
Figure 6. Global Spinal Muscular Atrophy (SMA) Drugs Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Application: 2024 VS 2031
Figure 8. Baby Case Studies
Figure 9. Child Case Studies
Figure 10. Adult Case Studies
Figure 11. Spinal Muscular Atrophy (SMA) Drugs Report Years Considered
Figure 12. Global Spinal Muscular Atrophy (SMA) Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Spinal Muscular Atrophy (SMA) Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Region: 2024 VS 2031
Figure 15. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Players in 2024
Figure 16. Global Top Spinal Muscular Atrophy (SMA) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Spinal Muscular Atrophy (SMA) Drugs as of 2024)
Figure 17. The Top 10 and 5 Players Market Share by Spinal Muscular Atrophy (SMA) Drugs Revenue in 2024
Figure 18. North America Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Spinal Muscular Atrophy (SMA) Drugs Market Share by Country (2020-2031)
Figure 20. United States Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Spinal Muscular Atrophy (SMA) Drugs Market Share by Country (2020-2031)
Figure 24. Germany Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Share by Region (2020-2031)
Figure 32. China Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Spinal Muscular Atrophy (SMA) Drugs Market Share by Country (2020-2031)
Figure 40. Mexico Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Share by Country (2020-2031)
Figure 44. Turkey Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Biogen Revenue Growth Rate in Spinal Muscular Atrophy (SMA) Drugs Business (2020-2025)
Figure 48. Novartis Revenue Growth Rate in Spinal Muscular Atrophy (SMA) Drugs Business (2020-2025)
Figure 49. Genentech Revenue Growth Rate in Spinal Muscular Atrophy (SMA) Drugs Business (2020-2025)
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed
Table 1. Global Spinal Muscular Atrophy (SMA) Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Oral Medicine
Table 3. Key Players of Injection Medicine
Table 4. Global Spinal Muscular Atrophy (SMA) Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Spinal Muscular Atrophy (SMA) Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Spinal Muscular Atrophy (SMA) Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Region (2020-2025)
Table 8. Global Spinal Muscular Atrophy (SMA) Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Region (2026-2031)
Table 10. Spinal Muscular Atrophy (SMA) Drugs Market Trends
Table 11. Spinal Muscular Atrophy (SMA) Drugs Market Drivers
Table 12. Spinal Muscular Atrophy (SMA) Drugs Market Challenges
Table 13. Spinal Muscular Atrophy (SMA) Drugs Market Restraints
Table 14. Global Spinal Muscular Atrophy (SMA) Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Players (2020-2025)
Table 16. Global Top Spinal Muscular Atrophy (SMA) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Spinal Muscular Atrophy (SMA) Drugs as of 2024)
Table 17. Ranking of Global Top Spinal Muscular Atrophy (SMA) Drugs Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Spinal Muscular Atrophy (SMA) Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Spinal Muscular Atrophy (SMA) Drugs, Headquarters and Area Served
Table 20. Global Key Players of Spinal Muscular Atrophy (SMA) Drugs, Product and Application
Table 21. Global Key Players of Spinal Muscular Atrophy (SMA) Drugs, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Type (2020-2025)
Table 25. Global Spinal Muscular Atrophy (SMA) Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Type (2026-2031)
Table 27. Global Spinal Muscular Atrophy (SMA) Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Application (2020-2025)
Table 29. Global Spinal Muscular Atrophy (SMA) Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Application (2026-2031)
Table 31. North America Spinal Muscular Atrophy (SMA) Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Spinal Muscular Atrophy (SMA) Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 46. Biogen Company Details
Table 47. Biogen Business Overview
Table 48. Biogen Spinal Muscular Atrophy (SMA) Drugs Product
Table 49. Biogen Revenue in Spinal Muscular Atrophy (SMA) Drugs Business (2020-2025) & (US$ Million)
Table 50. Biogen Recent Development
Table 51. Novartis Company Details
Table 52. Novartis Business Overview
Table 53. Novartis Spinal Muscular Atrophy (SMA) Drugs Product
Table 54. Novartis Revenue in Spinal Muscular Atrophy (SMA) Drugs Business (2020-2025) & (US$ Million)
Table 55. Novartis Recent Development
Table 56. Genentech Company Details
Table 57. Genentech Business Overview
Table 58. Genentech Spinal Muscular Atrophy (SMA) Drugs Product
Table 59. Genentech Revenue in Spinal Muscular Atrophy (SMA) Drugs Business (2020-2025) & (US$ Million)
Table 60. Genentech Recent Development
Table 61. Research Programs/Design for This Report
Table 62. Key Data Information from Secondary Sources
Table 63. Key Data Information from Primary Sources
Table 64. Authors List of This Report
List of Figures
Figure 1. Spinal Muscular Atrophy (SMA) Drugs Picture
Figure 2. Global Spinal Muscular Atrophy (SMA) Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Type: 2024 VS 2031
Figure 4. Oral Medicine Features
Figure 5. Injection Medicine Features
Figure 6. Global Spinal Muscular Atrophy (SMA) Drugs Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Application: 2024 VS 2031
Figure 8. Baby Case Studies
Figure 9. Child Case Studies
Figure 10. Adult Case Studies
Figure 11. Spinal Muscular Atrophy (SMA) Drugs Report Years Considered
Figure 12. Global Spinal Muscular Atrophy (SMA) Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Spinal Muscular Atrophy (SMA) Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Region: 2024 VS 2031
Figure 15. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Players in 2024
Figure 16. Global Top Spinal Muscular Atrophy (SMA) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Spinal Muscular Atrophy (SMA) Drugs as of 2024)
Figure 17. The Top 10 and 5 Players Market Share by Spinal Muscular Atrophy (SMA) Drugs Revenue in 2024
Figure 18. North America Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Spinal Muscular Atrophy (SMA) Drugs Market Share by Country (2020-2031)
Figure 20. United States Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Spinal Muscular Atrophy (SMA) Drugs Market Share by Country (2020-2031)
Figure 24. Germany Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Share by Region (2020-2031)
Figure 32. China Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Spinal Muscular Atrophy (SMA) Drugs Market Share by Country (2020-2031)
Figure 40. Mexico Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Share by Country (2020-2031)
Figure 44. Turkey Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Biogen Revenue Growth Rate in Spinal Muscular Atrophy (SMA) Drugs Business (2020-2025)
Figure 48. Novartis Revenue Growth Rate in Spinal Muscular Atrophy (SMA) Drugs Business (2020-2025)
Figure 49. Genentech Revenue Growth Rate in Spinal Muscular Atrophy (SMA) Drugs Business (2020-2025)
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Allergen Detection Market Research Report 2025
Jun 28, 25
Global Electronic Health Tracking System Market Research Report 2025
Jun 28, 25
Global Speciality Optical Fibers Market Research Report 2025
Jun 28, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232